Keyword

BRCAness

Description: A molecular phenotype in which cancer cells show features of BRCA1 or BRCA2 dysfunction, particularly impaired homologous recombination DNA repair.

Primary topic: PARP inhibition in cancer therapy (38%)

OpenAlex ID: keywords/brcaness

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

2016 · Giampaolo Bianchini, Justin M. Balko, et al. · Nature Reviews Clinical Oncology · 3,057

Hallmarks of 'BRCAness' in sporadic cancers

2004 · Nicholas Turner, Andrew Tutt, et al. · Nature reviews. Cancer · 1,660

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

2006 · Nuala McCabe, Nicholas C. Turner, et al. · Cancer Research · 1,311

BRCAness revisited

2016 · Christopher J. Lord, Alan Ashworth · Nature reviews. Cancer · 1,255

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

2017 · Helen Davies, Dominik Glodzik, et al. · Nature Medicine · 1,084

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

2018 · Andrew Tutt, Holly Tovey, et al. · Nature Medicine · 912

PDF

Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer

2010 · Panagiotis A. Konstantinopoulos, Dimitrios Spentzos, et al. · Journal of Clinical Oncology · 483

PDF

Targeting Topoisomerase I in the Era of Precision Medicine

2019 · Anish Thomas, Yves Pommier · Clinical Cancer Research · 339

CDK12 regulates DNA repair genes by suppressing intronic polyadenylation

2018 · Sara J. Dubbury, Paul L. Boutz, et al. · Nature · 314

PDF

Integrative genomic and transcriptomic analysis of leiomyosarcoma

2018 · Priya Chudasama, Sadaf S. Mughal, et al. · Nature Communications · 306

PDF

Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer

2017 · Likun Li, Styliani Karanika, et al. · Science Signaling · 296

Biology and Management of Patients With Triple-Negative Breast Cancer

2016 · Priyanka Sharma · The Oncologist · 292

PDF

Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy

2012 · Ignacio Romero, Robert C. Bast · Endocrinology · 286

PCAT-1 , a Long Noncoding RNA, Regulates BRCA2 and Controls Homologous Recombination in Cancer

2014 · John R. Prensner, Wei Chen, et al. · Cancer Research · 251

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers

2013 · E H Lips, L Mulder, et al. · British Journal of Cancer · 232

PDF

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer

2020 · H.P. Eikesdal, S. Yndestad, et al. · Annals of Oncology · 221

PDF

Replication Gaps Underlie BRCA Deficiency and Therapy Response

2020 · Nicholas J. Panzarino, John Krais, et al. · Cancer Research · 213

PDF

Defining and Modulating ‘BRCAness’

2019 · Andrea K. Byrum, Alessandro Vindigni, et al. · Trends in Cell Biology · 167

Hereditary breast and ovarian cancer susceptibility genes (Review)

2013 · HIROSHI KOBAYASHI, SUMIRE OHNO, et al. · Oncology Reports · 163

PDF

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

2014 · Kyungsoo Ha, Warren Fiskus, et al. · Oncotarget · 157

PDF

Bortezomib-induced “BRCAness” sensitizes multiple myeloma cells to PARP inhibitors

2011 · Paola Neri, Li Ren, et al. · Blood · 157

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers

2019 · Man Keung, Yanyuan Wu, et al. · Journal of Clinical Medicine · 154

PDF

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies

2018 · Ji Hyun Park, Jin-Hee Ahn, et al. · ESMO Open · 152

Helicobacter pylori CagA elicits BRCAness to induce genome instability that may underlie bacterial gastric carcinogenesis

2021 · Satoshi Imai, Takuya Ooki, et al. · Cell Host & Microbe · 150

PDF

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

2020 · Florence Coussy, Rania El-Botty, et al. · Science Translational Medicine · 147

Works count: 786

Citation count: 21,690